In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

Recent health updates highlight the FDA's approval of Lantheus' new prostate cancer imaging agent to enhance production ...

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided system that combines magnetic resonance imaging (MRI) with precise prostate ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

The FDA approved a new Lantheus prostate cancer imaging agent. South Carolina's measles cases rise. Medtronic's MiniMed shares drop in Nasdaq debut. A French probe exonerates Nestle in a baby death ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

Jeffrey Epstein's Zorro Ranch became his in 1993 after he purchased it from the family of former New Mexico Governor Bruce ...

Jill Biden is breaking her silence about Joe Biden’s decision to abruptly end his 2024 presidential reelection bid under pressure from ...

For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...

Disable Army veteran Jose Fernandez said it was only after he threatened to file a disability claim that they finally let him ...